^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Gazyva (obinutuzumab) (CD20 inhibitor) + Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
CLL/SLL without del(17p)/TP53 mutation, First-line therapy, Frail patient with significant comorbidity…Acalabrutinib ± obinutuzumab was changed from a category 2A recommendation to a category 1 recommendation.
